Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 0.65 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.65 |
| ▸ | RAF1 | P04049 | 2/20 | 0.65 |
| ▸ | KDR | P35968 | 2/20 | 0.65 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.65 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.65 |
| ▸ | NEK2 | P51955 | 2/20 | 0.65 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.65 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.65 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.65 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.65 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 0.65 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.65 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.65 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.65 |
| ▸ | PLK4 | O00444 | 1/20 | 0.65 |
| ▸ | PIR | O00625 | 1/20 | 0.65 |
| ▸ | AURKA | O14965 | 1/20 | 0.65 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.65 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7869149 | 0.92 | BRAF (0.71) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298900 | 0.90 | BRAF (0.80) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL294160 | 0.89 | BRAF (0.82) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL29796757 | 0.89 | BRAF (0.82) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298459 | 0.88 | CYP2C9 (0.64) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL29482896 | 0.88 | CYP2C9 (0.64) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL855439 | 0.88 | BRAF (0.67) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL299371 | 0.88 | BRAF (0.73) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL299394 | 0.87 | BRAF (0.63) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL20294639 | 0.87 | BRAF (0.67) | BRAFRIPK2RAF1KDRMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893612-B1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC (US) | 2011-08-03 | — | — | EP | claimed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | claimed |
| US-8143271-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120053177-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-01-26 | — | — | US | disclosed |
| EP-1893612-B1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2011-03-10 | — | — | US | disclosed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053177-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRAF 48/4885RIPK2 514/4885RAF1 78/4885 |
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRAF 48/4885RIPK2 514/4885RAF1 78/4885 |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRAF 48/4885RIPK2 514/4885RAF1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.